A 58-year-old with biochemically recurrent prostate cancer is scheduled for a receptor-targeted PET study. The radiopharmacy holds an on-site germanium-68/gallium-68 generator with lyophilized kits, and the only PET radiopharmacy shipment this week carries FDG from the local cyclotron. Which radiopharmaceutical meets the targeting and on-site preparation needs?
Select an answer to reveal the explanation.
Short Explanation
Gallium-68 PSMA-11 targets PSMA and can be prepared from your on-site generator eluate using a cold kit, then assayed before dosing. It’s like making a meal with ingredients already on your shelf instead of waiting for a delivery truck.
Full Explanation
PSMA-11 fits because it is the PSMA-targeting agent the department can prepare from its own germanium-68/gallium-68 generator. Fresh eluate is added to the lyophilized kit, allowed to stand per package directions, and assayed before the dose is drawn. DCFPyL targets PSMA, but it requires a cyclotron shipment that is unavailable this week. DOTATATE targets somatostatin receptors, not PSMA, even though its kit preparation matches the department's equipment. FDG is available from the shipment but reports glucose metabolism rather than PSMA expression, so it does not meet the receptor-targeting requirement. Exam caveat: when a stem supplies both an agent constraint and a preparation constraint, both must be satisfied. Practical check: verify the kit expiration, the eluate activity, and the assay reading before drawing the patient dose.